| Gregory Michael Maggio, DO | |
|
3901 Rainbow Blvd, Kansas City, KS 66160-8500 | |
| (630) 267-1803 | |
| Not Available |
| Full Name | Gregory Michael Maggio |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 6 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790278364 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 94-09538 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Boise State University researchers have created anti-cancer drugs that are effective at killing 58 of the 60 types of tumors found in the National Cancer Institutes NCI-60 panel of cancer cells, which affect nine organ systems in the human body.
Warner Chilcott plc announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) to its New Drug Application submitted in March 2009 for its "low dose" oral contraceptive (also referred to as WC 3016).
Patients with Alzheimer's disease have a higher risk of developing glioblastoma and a lower risk of lung cancer.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
› Verified 4 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Boise State University researchers have created anti-cancer drugs that are effective at killing 58 of the 60 types of tumors found in the National Cancer Institutes NCI-60 panel of cancer cells, which affect nine organ systems in the human body.
Warner Chilcott plc announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) to its New Drug Application submitted in March 2009 for its "low dose" oral contraceptive (also referred to as WC 3016).
Patients with Alzheimer's disease have a higher risk of developing glioblastoma and a lower risk of lung cancer.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Michael Maggio, DO 6916 N Pontiac Ave, Kansas City, MO 64151-8234 Ph: (630) 267-1803 | Gregory Michael Maggio, DO 3901 Rainbow Blvd, Kansas City, KS 66160-8500 Ph: (630) 267-1803 |
News Archive
Boise State University researchers have created anti-cancer drugs that are effective at killing 58 of the 60 types of tumors found in the National Cancer Institutes NCI-60 panel of cancer cells, which affect nine organ systems in the human body.
Warner Chilcott plc announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) to its New Drug Application submitted in March 2009 for its "low dose" oral contraceptive (also referred to as WC 3016).
Patients with Alzheimer's disease have a higher risk of developing glioblastoma and a lower risk of lung cancer.
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
› Verified 4 days ago
Joan M. T. Collison, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd # Ms 4015, Kansas City, KS 66160 Phone: 913-588-1300 Fax: 913-588-1310 | |
Dr. Andrea Lee, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3599 Rainbow Blvd, Kansas City, KS 66103 Phone: 913-588-6970 | |
James S Appelbaum, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 8919 Parallel Pkwy, Suite 440, Kansas City, KS 66112 Phone: 913-596-7286 Fax: 913-596-7248 | |
Dr. Robert T. Reynders, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Ms 1020, Kansas City, KS 66160 Phone: 913-588-3807 | |
Ahmad Abuzinadah, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Ms 2012, Kansas City, KS 66160 Phone: 913-588-6970 Fax: 913-588-6965 | |
Dr. Thomas Bryan Hall, Iii, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Department Of Psychiatry, Kansas City, KS 66160 Phone: 913-588-6400 | |
Debra Jean Kelsh, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-1304 Fax: 913-588-1310 |